Kirn D - Search Results

1

Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.

Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T, Landers S, Maples P, Romel L, Randlev B, Reid T, Kaye S, Kirn D. Nemunaitis J, et al. Among authors: kirn d. Cancer Res. 2000 Nov 15;60(22):6359-66. Cancer Res. 2000. PMID: 11103798 Clinical Trial.

2

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer.

Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, Gore M, Ironside J, MacDougall RH, Heise C, Randlev B, Gillenwater AM, Bruso P, Kaye SB, Hong WK, Kirn DH. Khuri FR, et al. Among authors: kirn dh. Nat Med. 2000 Aug;6(8):879-85. doi: 10.1038/78638. Nat Med. 2000. PMID: 10932224 Clinical Trial.

3

Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer.

Nemunaitis J, Khuri F, Ganly I, Arseneau J, Posner M, Vokes E, Kuhn J, McCarty T, Landers S, Blackburn A, Romel L, Randlev B, Kaye S, Kirn D. Nemunaitis J, et al. Among authors: kirn d. J Clin Oncol. 2001 Jan 15;19(2):289-98. doi: 10.1200/JCO.2001.19.2.289. J Clin Oncol. 2001. PMID: 11208818 Clinical Trial.

4

Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity.

Nemunaitis J, Cunningham C, Buchanan A, Blackburn A, Edelman G, Maples P, Netto G, Tong A, Randlev B, Olson S, Kirn D. Nemunaitis J, et al. Among authors: kirn d. Gene Ther. 2001 May;8(10):746-59. doi: 10.1038/sj.gt.3301424. Gene Ther. 2001. PMID: 11420638 Clinical Trial.

5

A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.

Ganly I, Kirn D, Eckhardt G, Rodriguez GI, Soutar DS, Otto R, Robertson AG, Park O, Gulley ML, Heise C, Von Hoff DD, Kaye SB. Ganly I, et al. Among authors: kirn d. Clin Cancer Res. 2000 Mar;6(3):798-806. Clin Cancer Res. 2000. PMID: 10741699 Clinical Trial.

6

Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints.

Reid T, Galanis E, Abbruzzese J, Sze D, Wein LM, Andrews J, Randlev B, Heise C, Uprichard M, Hatfield M, Rome L, Rubin J, Kirn D. Reid T, et al. Among authors: kirn d. Cancer Res. 2002 Nov 1;62(21):6070-9. Cancer Res. 2002. PMID: 12414631 Clinical Trial.

7

Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial.

Mulvihill S, Warren R, Venook A, Adler A, Randlev B, Heise C, Kirn D. Mulvihill S, et al. Among authors: kirn d. Gene Ther. 2001 Feb;8(4):308-15. doi: 10.1038/sj.gt.3301398. Gene Ther. 2001. PMID: 11313805 Clinical Trial.

8

Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer.

Vasey PA, Shulman LN, Campos S, Davis J, Gore M, Johnston S, Kirn DH, O'Neill V, Siddiqui N, Seiden MV, Kaye SB. Vasey PA, et al. Among authors: kirn dh. J Clin Oncol. 2002 Mar 15;20(6):1562-9. doi: 10.1200/JCO.2002.20.6.1562. J Clin Oncol. 2002. PMID: 11896105 Clinical Trial.

9

A novel assay to assess primary human cancer infectibility by replication-selective oncolytic adenoviruses.

Wang Y, Thorne S, Hannock J, Francis J, Au T, Reid T, Lemoine N, Kirn D, Halldén G. Wang Y, et al. Among authors: kirn d. Clin Cancer Res. 2005 Jan 1;11(1):351-60. Clin Cancer Res. 2005. PMID: 15671566

10

Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status.

Heise C, Ganly I, Kim YT, Sampson-Johannes A, Brown R, Kirn D. Heise C, et al. Among authors: kirn d. Gene Ther. 2000 Nov;7(22):1925-9. doi: 10.1038/sj.gt.3301319. Gene Ther. 2000. PMID: 11127580

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

185 results

Search Page